Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

计划入组 5 人 · 首次发布于 2019 年 6 月 4 日

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

计划入组 4 人 · 首次发布于 2020 年 3 月 17 日

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

计划入组 6 人 · 首次发布于 2019 年 6 月 5 日

BRAF-V600E degrader

DPX BRAF/CPA

BRAF kinase inhibitor (Ruga Corporation)

BRAC UNIVERSITY

Bangladesh

BRAY GROUP LIMITED

United Kingdom

C4 Therapeutics' CFT1946 Shows Promise in BRAF V600 Mutant Solid Tumors

Labcorp's PGDx elio Tissue Complete CDx Gains FDA Approval as Companion Diagnostic for BRAF-Mutant Advanced Melanoma

Phase 3 Trial Shows Promise for Adjuvant BRAF/MEK Inhibitor Combination in High-Risk Melanoma